Table 4.
Treatment-related toxicities in the 50 patients with locally advanced/metastatic pancreatic cancer, 18 patients receiving a full dose compared with the 32 patients receiving an attenuated dose
| Toxicity | Any grade n (%) |
Grade ¾ n (%) |
p-valuea |
|---|---|---|---|
| Neutropenia (All patients=50) | 28 (56) | 16 (32) | 0.01 |
| Receiving an attenuated dose (n=32) | 15 (46.9) | 6 (18.8) | |
| Receiving a full dose (n=18) | 13 (72.2) | 10 (55.6) | |
| Febrile neutropenia (all patients=50) | 3 (6) | 3 (6) | 1 |
| Receiving an attenuated dose (n=32) | 2 (6.3) | 2 (6.3) | |
| Receiving full dose (n=18) | 1 (5.6) | 1 (5.6) | |
| Thrombocytopenia (all patients=50) | 17 (34) | 3 (6) | 0.29 |
| Receiving an attenuated dose (n=32) | 11 (34.4) | 1 (3.1) | |
| Receiving a full dose (n=18) | 6 (39.3) | 2 (11.1) | |
| Anemia (all patients=50) | 29 (58) | 6 (12) | 0.02 |
| Receiving an attenuated dose (n=32) | 13 (40.6) | 1 (3.1) | |
| Receiving a full dose (n=18) | 16 (88.9) | 5 (27.8) | |
| Fatigue (all patients=50) | 30 (60) | 11 (22) | 0.01 |
| Receiving an attenuated dose (n=32) | 14 (43.8) | 3 (9.4) | |
| Receiving a full dose (n=18) | 16 (88.9) | 8 (47.1) | |
| Diarrhoea (all patients=50) | 13 (26) | 3 (6) | 0.29 |
| Receiving an attenuated dose (n=32) | 8 (25) | 1 (3.1) | |
| Receiving a full dose (n=18) | 5 (27.8) | 2 (12.5) | |
| Vomiting (all patients=50) | 32 (64) | 4 (8) | 0.01 |
| Receiving an attenuated dose (n=32) | 15 (46.9) | 0 (0) | |
| Receiving a full dose (n=18) | 17 (94.4) | 4 (23.5) | |
| Peripheral sensory neuropathy (all patients=50) | 10 (20) | 4 (8) | 0.13 |
| Receiving an attenuated dose (n=32) | 5 (15.6) | 1 (3.1) | |
| Receiving a full dose (n=18) | 5 (29.4) | 3 (17.6) |
Note: ap-value calculated using Fisher’s exact test.